Scouting report · CMPS
Kabir Nath
Ex-BMS and Otsuka pharma executive; COMPASS Pathways CEO since August 2022
- Born / age
- (61)
- Role
- Chief Executive Officer & Director
- In the role
- 4 yr
- Education
- MA King's College, University of Cambridge
- Front Office rank
- not ranked yet
CMPS
COMPASS Pathways plcBiotech binary
- Title
- Chief Executive Officer & Directorsrc
- In role
- since 2022-08 (4 yr)
Stake value—no holding or price on file
—thin record
Scouting sheetas of 25 Sep 2026
Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design40strategic, time only · 99.2% for · company lost money
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
99%Say-on-pay
—Airtime on calls
- Beat
- 0
- Met
- 0
- Missed
- 0
- Withdrawn
- 0
- Still open
- 0
- Answers on calls
- 0
- Questions dodged
- 0
- Dodges / 100 answers
- —
Personal and ownership data
What to weigh
Watch 6
- All equity pay is time-vested (market-priced options plus RSUs or nominal-cost options), with no performance condition. The cash bonus rests on board-assessed corporate goals, which scored 100% for 2025src
- April 2025 amendment: all time-based equity vests in full on termination without cause or good-reason resignation within 12 months of a change in controlsrc
- UK contract: 15 months' notice pay in lieu plus target bonus. The move to the UK cost the company a $250,000 relocation payment plus £12,000 a month housing through August 2023, and he gets a tax-advice allowancesrc
- Joining grant in 2022: $6.42m of options and $0.75m of stock awards, making his 2022 pay $7.64m for five monthssrc
- Owns 58,190 ADSs outright. Nearly all of his 1.02m beneficial holding (about 0.75% with options) is 959,200 exercisable options. No open-market buys or sells in the last 12 monthssrc
- Pre-revenue: GAAP net loss grew from $118.5m (FY2023) to $155.1m (FY2024) and $287.9m (FY2025), funded by repeated equity raisessrc
In their favour 1
- Hedging and pledging of company shares are banned under the insider trading policysrc
Pay
Salary and otherBonus, stock, options, incentive
The table
- Bonus pays on
- Cash bonus at a target of 60% of salary (cap 125% of target) on board-assessed corporate goals (NDA readiness, PTSD expansion, cash runway, launch prep, culture). 2025 scored 100% and he was paid $388,367
- Long-term award pays on
- Annual grants of market-priced options (275,000 in 2025) and RSUs or nominal-cost options (92,000). All time-vested, no performance conditionsrc
- Pay at risk not on file
- Pays on returns strategic, time only
- Shareholder vote 99.2% for
- Pay vs profit company lost money
Career
- 2022-08 – nowCOMPASS Pathways plcsrc
Chief Executive Officer & Director
Initially US-based; relocated to the UK in Q2 2024 under a new UK employment agreement - 2020-03 – 2022-07
- 2016-03 – 2022-04
- 2003 – 2015-12Bristol-Myers Squibbsrc
Positions of increasing responsibility and leadership
Per company and Otsuka bios found by search: joined in Singapore in 2003 as VP South East Asia/Taiwan/Hong Kong; President BMS China from 2005; President Asia Pacific Medicines from 2008; later SVP Virology, Transplant & Optimized Brands and SVP Global Commercialization, Virology & Neuroscience
Not located: Career before 2003 not located (the 2022 appointment 8-K says about thirty years in biopharma and medical devices); 2016-01 to 2016-03 between BMS and Otsuka not described
The promise ledger
No promise on the record yet: the research routine has not scored this company's guidance.
Background
- Family The 2026 proxy states there are no family relationships among any directors or executive officers; the 2022 appointment 8-K said the same for himsrc
- Boards Director of the American Foundation for Suicide Preventionsrc
- Other Came from Otsuka, where he ran North American pharma. COMPASS director Robert McQuade also spent 2004-2023 at Otsuka Pharmaceutical Development & Commercialization. An LLC McQuade manages holds 1.59m COMPASS ADSssrc
- Other The 2022 appointment 8-K says no Item 404(a) related-party transactions and no arrangement behind his appointmentsrc
Sources14
- Filing COMPASS Pathways plc DEF 14A (accession 0001193125-26-157123) · 2026-04-15
- Filing COMPASS Pathways plc DEF 14A (accession 0001816590-25-000051) · 2025-04-28
- Filing COMPASS Pathways plc DEF 14A (accession 0001816590-24-000070) · 2024-04-08
- Filing COMPASS Pathways 8-K Item 5.02, appointment of Kabir Nath as CEO (0001816590-22-000073) · 2022-07-19
- Filing COMPASS Pathways 8-K Item 5.02(e), change-in-control vesting amendments (0001816590-25-000042) · 2025-04-16
- Filing COMPASS Pathways 8-K Item 8.01, COMP005 Phase 3 primary endpoint (0001816590-25-000085) · 2025-06-23
- Filing COMPASS Pathways 8-K Item 8.01, COMP006 Phase 3 primary endpoint (0001816590-26-000007) · 2026-02-17
- Filing COMPASS Pathways 8-K Item 1.01, underwriting agreement for $150m ADS offering (0001628280-26-009501) · 2026-02-19
- Filing COMPASS Pathways 8-K Item 8.01, COMP006 26-week results and NDA timing (0001816590-26-000047) · 2026-07-07
- Filing COMPASS Pathways 8-K Item 5.07, 2026 AGM results (0001816590-26-000046) · 2026-05-28
- Filing COMPASS Pathways 10-Q for the quarter ended 2026-06-30, signatures (0001816590-26-000058) · 2026-08-05
- Filing SEC XBRL companyconcept us-gaap/NetIncomeLoss, CIK 1816590 (FY2025 10-K, 0001816590-26-000020) · 2026-03-24
- Filing SEC EDGAR ownership report listing (Forms 3/4/5) for issuer CIK 1816590; Kabir Nath reporting CIK 1940258 · 2026-09-25
- Web search result WebSearch: Kabir Nath Bristol-Myers Squibb / Otsuka North America biography (Otsuka US leadership page and company bios) · 2026-09-25